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Abstract:  MicroRNAs  (miRNAs)  are  small  non-coding  RNAs  of  ~22  nucleotides  that 
function  as  negative  regulators  of  gene  expression  by  either  inhibiting  translation  or 
inducing deadenylation-dependent degradation of target transcripts. Notably, deregulation 
of miRNAs expression is associated with the initiation and progression of human cancers 
where they act as oncogenes or tumor suppressors contributing to tumorigenesis. Abnormal 
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miRNA expression may provide potential diagnostic and prognostic tumor biomarkers and 
new therapeutic targets in cancer. Recently, several miRNAs have been shown to initiate 
invasion  and  metastasis  by  targeting  multiple  proteins  that  are  major  players  in  these 
cellular  events,  thus  they  have  been  denominated  as  metastamiRs.  Here,  we  present  a 
review of the current knowledge of miRNAs in cancer with a special focus on metastamiRs. 
In addition we discuss their potential use as novel specific markers for cancer progression. 
Keywords:  microRNA;  cancer;  epithelial-mesenchymal  transition;  invasion;  
metastasis; metastamiRs 
 
Abbreviations:  microRNA  (miRNA);  RNA  polymerase  II  (RNA  pol  II);  DiGeorge  syndrome 
critical  region  gene  8  (DGCR8);  primary-miRNA  (pri-miRNA);  precursor  miRNA  (pre-miRNA), 
precursor  mRNA  (pre-mRNA);  3′  untranslated  region  (3′-UTR);  RNA-induced  silencing  complex 
(RISC); TAR RNA-binding protein (TRBP); Argonaute (AGO). 
1. Introduction 
Cancer represents a heterogeneous group of diseases characterized by uncontrolled growth of cells, 
high  proliferation,  apoptosis  resistance,  acquisition  of  invasive  properties  to  adjacent  tissues  and 
organs,  and  inappropriate  survival  of  cells,  which  results  in  tumors  formation.  The  puzzling 
complexity of cancer properties was outlined as the “hallmarks of cancer” a decade ago in the seminal 
report of Hanahan and Weinberg [1], and it comprises six essential alterations in cell physiology that 
collectively  dictate  malignant  growth:  (i)  self-sufficiency  in  growth  signals;  (ii)  insensitivity  to  
anti-growth  signals;  (iii)  evasion  of  apoptosis;  (iv)  limitless  replicative  potential;  (v)  sustained 
angiogenesis; and (vi) tissue invasion and metastasis [1,2]. Notably, the acquired capabilities of cancer 
cells to invade and metastasize to other tissues and organs represent the most deadly hallmark of 
malignant tumors [3]. Normal cells have developed several safeguards and checkpoints to regulate the 
above mentioned cellular features. These cellular processes are tightly regulated by protein-encoding 
genes  whose  expression  switches-on  or  -off  during  development  and  in  the  adult  body.  Altered 
versions of these genes referred to as tumor-suppressor genes and oncogenes, arise in a multistep 
process in cells populations that are clonally selected to cause cancer [4]. However, this view has 
begun to change as new molecular players in cancer have been identified, which suggests an additional 
level  of  complexity  in  the  mechanisms  leading  to  tumorigenesis.  In  the  last  decade,  it  has  been 
reported that an abundant class of small non-coding single-stranded RNAs of ~22 nucleotides, dubbed 
as microRNAs (miRNA) function as negative regulators of gene expression and may have important 
roles in the development of cancer. An increasing number of studies are showing that the expression of 
miRNAs  is  deregulated  in  almost  all  human  malignancies.  Functional  characterization  of  these 
aberrantly  expressed  miRNAs  indicates  that  they  might  also  function  as  oncogenes  and  
tumor-suppressors, thus they have been collectively named as “oncomirs” [5]. Here we review the 
current knowledge of the roles of miRNAs in cancer with a special focus on miRNAs involved in 
metastasis, known as metastamiRs. Int. J. Mol. Sci. 2012, 13  1349 
 
2. Mechanisms of Invasion and Metastasis  
Metastasis is the result of cancer cells detaching from a primary tumor, consequently adapting to 
distant tissues and organs, and forming a secondary tumor [6]. The ability to metastasize is a hallmark 
of malignant tumors [1]. Cancer cells should successfully complete multiple sequential steps, such as 
spread  from  tumor  of  origin,  motility,  intravasation,  survival  in  the  circulation,  extravasation  and 
colonization, before they will grow and proliferate in a secondary site to form a new tumor [7,8] (Figure 1). 
Although it is well established that metastasis is a complex multistep event, it occurs through distinct 
temporal kinetics for each type of cancer, according to primary tumor origin and the ability of cells to 
invade specific distant tissues and organs [9]. The capability of cancer cells to metastasize depends on 
genetic and epigenetic events that are acquired during tumor progression [3]. Molecular and genetics 
modifications that conditioned cancer cell to be metastatic might depend on initial mutations, which 
maintain genomic instability that will generate oncogenically transformed cells [10]. Nevertheless, it 
remains unclear if oncogenic transformation is sufficient for metastatic competence. The long latency 
period of certain tumors types suggests a further evolution of malignant cells in the microenvironments 
of particular organs [11]. 
Genes and proteins participating in metastasis are related to distinct biological processes, such as 
interaction  with  the  local  microenvironment,  migration,  invasion,  resistance  to  apoptosis,  and  the 
ability  to  induce  angiogenesis  [10,12]  (Figure  1).  Genes  that  allow  cancer  cell  to  invade  the 
surrounding tissues  attract  a  supportive  stroma  and  facilitate cellular dispersion and infiltration in 
distant tissues, are known as metastasis initiation genes [6]. These include transcription factors, growth 
factors receptors, protein kinases and recently, miRNAs [13,14]. These genes participate in regulation 
of motility, epithelial-mesenchymal transition (EMT), adhesion and proteolysis, in order to determine 
tumor cell interaction with other cells and with the extracellular matrix, create a path for migration, 
promote  angiogenesis,  and  both  directly  and  indirectly  trigger  survival  signals  [15].  Cell 
transformation  results  in  major  phenotypic  changes,  including  cell  surface  receptor  expression, 
cytoskeletal  function,  growth  factor  and  cytokine  secretion,  proteolytic  enzyme  production,  and  the 
glycosyltransferase  and  glycosidase  repertoire  expression,  which  affects  adhesive  properties  [16]. 
Carcinoma cells interactions with the extracellular matrix are mediated by integrins and play a key role 
in tumor invasion and spread. Integrins trigger both signals that organize and remodel the cytoskeleton 
of the cell; provide polarity, and proliferation and survival control. Integrins promote invasion and 
proliferation and they determine whether cells migrate and proliferate in response to cytokines and 
growth factors [17]. Cells that become detached from the epithelium display loss of adherent junctions, 
which,  in  epithelial  cells,  are  constituted  primarily  by  E-cadherin.  E-cadherin  is  replaced  by  N-
cadherin, which plays an important role in invasion by regulating fibroblast growth factor receptor 
(FGFR) function [18]. This process, known as the cadherin switch, is associated with EMT. This 
change is referred as  the  conversion of epithelial cells  to motile, fibroblast-like cells  that express 
mesenchymal rather than epithelial cell markers [19]. Int. J. Mol. Sci. 2012, 13  1350 
 
Figure 1. Mechanisms of invasion and metastasis. During metastatic process, tumor cells 
detached from primary tumor, acquire motility, degrade basal membrane, and survive in 
circulation within blood and lymphatic vessels. Then, circulating tumor cells are able to 
colonize a secondary organ, where they can survive, proliferate and form an additional 
tumor. Genes and molecules that participate in these mechanisms have been identified, 
including some miRNAs. The time between each metastatic event is variable according to 
primary  tumor  kinds,  therefore  molecular  and  epigenetic  changes  in  tumor  cells  types 
might also be variable. 
 
To generate an  invasive tumor,  cancer cells  should  also  enter to  circulation and survive there, 
regardless of development of clinical metastasis. The acquisition of prometastatic function early during 
primary tumor formation might enable other cancer subtypes to relapse more quickly. Therefore, the 
typical steps of metastasis might be the same in all tumor types, including general invasive activities 
that are conferred by the expression of metastasis initiation genes. But metastasis to different organs 
might require distinct sets of infiltration and colonization functions, which are acquired over variable 
periods of time [6]. Accordingly, these capabilities can be provided by genes that are deregulated in 
primary cancer cells; these genes are known as metastatic progression genes, and they could have 
different functions at the primary site and in distant organ. Examples of these factors include matrix 
metalloproteinases  (MMP),  COX2  and  cytokines  [6].  Epithelial  cell  communicating  with  their Int. J. Mol. Sci. 2012, 13  1351 
 
microenvironment is regulated by E-cadherin-mediated cell-cell interaction and β1-integrin-mediated 
adhesion to the basement membrane (BM), which is the first barrier to invasion by carcinoma cells. 
MMP can degrade the various components of the BM, such as collagen IV, by proteolysis [20]. In 
addition to these essential roles in the early steps of tumor metastasis, MMP-2 activation promotes 
angiogenesis [21], one of the prerequisites for metastatic tumor growth [22]. MMP-2 degrades the 
fibrin matrix that surrounds newly formed blood vessels, facilitating endothelial cell penetration of 
tumor tissue [21]. Genes that are essential for the metastatic colonization of a certain organ become 
expressed  only  in  cancer  cells  that  have  successfully  achieved  the  previous  steps  of  metastasis 
initiation and progression. Examples of these genes are parathyroid hormone-related protein (PTHRP), 
interleukin 11, granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 6 and TNF-α, 
promoting cancer cell passage through capillary walls and survival in the newly invaded tissue [23–25]. 
The  selection  for  activated  developmental  pathways  might  also  enhance  metastatic  competence  to 
multiple organs by enforcing this plasticity and providing strong invasive and adaptation functions to 
cancer  cells.  In  summary,  identification  of  the  mechanisms  that  promote  metastatic  progression 
without latent speciation might provide novel therapeutic targets for early intervention. 
3. Biogenesis of microRNAs 
miRNAs are small non-coding single-stranded RNAs of ~22 nucleotides in length which function at 
post-transcriptional level as negative regulators of gene expression, and they are found in both plants 
and animals (for review see [26]). miRNAs are generated as endogenous hairpin-shaped long transcripts 
and function as guide molecules by base pairing with the target messenger RNA (mRNA) inducing 
translation repression or transcripts cleavage (for review see [27]). Annotation of genomic positions of 
miRNAs indicates that most miRNAs genes are located in intergenic regions, but they are also found 
within exonic or intronic regions in either sense or antisense orientation. The miRNAs localized within 
introns of protein-encoding or -non-encoding genes have been denominated “mirtrons” [28]. miRNAs 
may  be  organized  as  individual  genes  or  be  localized  together  as  clusters  representing  miRNAs 
families which are commonly related in sequence and function. miRNAs are transcribed by the RNA 
polymerase II (RNA pol II) from their own promoter or from promoter of the host gene in which they 
reside. RNA pol II synthesized large miRNA precursors called primary-miRNAs (pri-miRNAs) [29]. 
Clustered  miRNAs  might  be  transcribed  from  a  single  transcription  unit  as  polycistronic  
primary-miRNA. Notably, pri-miRNAs contain both 5′-cap structure (
7MGpppG) as well as 3′-end 
poly(A) tail [30]. The initial step (cropping) in pri-miRNA processing is performed in the nucleus by 
the  enzymatic  activity  of  an  RNAse  III-type  protein  called  Drosha  associated  to  a  double  
stranded-RNA-binding protein DGCR8 (DiGeorge syndrome critical region gene 8; Pasha in flies) 
known as the microprocessor complex, that generates ~70-nucleotides precursor miRNA (pre-miRNA) 
products, which locally fold into stable secondary stem-loop structures [31]. The pre-miRNAs are then 
exported into the cytoplasm by the Ran-GTP-dependent transporter exportin 5 [32,33]. Pre-miRNA 
has a short stem plus a ~2-nt 3′ overhang, which is recognized by the nuclear export factor exportin 5. 
The second step of pre-miRNA processing (dicing) is performed by the RNAse III enzyme Dicer 
(Dicer 1 in flies) associated to TRBP (TAR RNA-binding protein) or PACT (also known as PRKRA), 
and  Argonaute  (AGO1-4),  which  cleave  the  miRNA  precursor  hairpin  generating  a  transitory  Int. J. Mol. Sci. 2012, 13  1352 
 
double-stranded  RNA  of  ~22  nucleotides  in  length  referred  as  miRNA:miRNA*  duplex,  where 
miRNA is known as the mature miRNA guide which remains associated to AGO, and miRNA* is 
denominated the passenger strand which is subsequently degraded. This duplex is then loaded into the 
miRNA associated RNA-induced silencing complex (RISC), which preferentially includes the mature  
single-stranded miRNA molecule and AGO proteins, where they act as guiding molecules to deliver 
the complex to target mRNA. It seems that AGO is associated to Dicer in the dicing step as well as in 
the  RISC  assembly  step.  The  mature  miRNA  then  hybridizes  to  complementary  sites  in  the  3′ 
untranslated regions (3′-UTR) of mRNA targets to negatively regulate gene expression in one of two 
ways that depend on the degree of complementarity between the miRNA and its target. miRNAs that 
bind to mRNA targets with imperfect complementarity lead to translational repression and exonucleolytical 
mRNA decay; whereas miRNAs that bind to their mRNA targets with high complementarity induce 
endonucleolytical cleavage of target-mRNA [34]. 
Several findings suggested that miRNAs biogenesis and function are becoming more complex than 
previously thought. It has been proposed that canonical and non-canonical intronic miRNAs (mirtrons) 
follow  alternative  pathways  for  miRNA  biogenesis  [27].  Canonical  mirtrons  are  processed  
co-transcriptionally before splicing. The splicing commitment complex is thought to tether the introns 
while  Drosha  cleaves  the  miRNA  hairpin.  The  pre-miRNA  enters  the  classical  miRNA  pathway, 
whereas the rest  of the transcript undergoes  precursor  mRNA  (pre-mRNA) splicing and  produces 
mature mRNA for protein synthesis. In non-canonical pathway, mirtrons are produced from spliced 
introns  as  debranched  introns  that  mimic  the  structural  features  of  pre-miRNAs  to  enter  to  
miRNA-processing pathway without Drosha-mediated cleavage. Because mirtrons can derive from 
small  introns  that  resemble  pre-miRNAs,  they  bypass  the  Drosha-processing  step.  Notably,  some 
introns  have  tails  at  either  the  5′  end  or  3′  end,  so  they  need  to  be  trimmed  before  pre-miRNA  
export (Figure 2). Other reports showed the diverse functions of miRNAs. It has been reported that 
miRNAs may alternatively activate mRNA translation during cell cycle [34]. In addition, it has been 
evidenced that mature miRNAs may also be localized in nucleus, through a specific hexanucleotide 
(AGUGUU) sequence which acts as a transferable nuclear localization element [35]. Moreover, it has 
been  shown  that  vesicles  of  endocytic  origin  known  as  exosomes  may  contain  both  mRNA  and 
microRNAs, which can be delivered to another cell, and can be functional in this new location. These 
RNA molecules were denominated exosomal shuttle RNAs as they mediate exchange of miRNAs with 
other cells, which represents a novel mechanism of genetic exchange [36]. Overall, these amazing 
findings motivate searches for currently unidentified functions for miRNAs. Int. J. Mol. Sci. 2012, 13  1353 
 
Figure 2. Biogenesis of microRNAs. The processing of miRNAs is mediated by Dicer and 
Drosha endonucleases. In the first step, the microprocessor complex (Drosha and DGCR8) 
mediates  the  nuclear  processing  of  the  primary-miRNAs  (pri-miRNA)  into  stem-loop 
precursors  of  ~70  nucleotides  (pre-miRNA).  The  nuclear  export  of  the  precursors  is 
subsequently mediated by exportin-5 in a Ran-GTP dependent manner. In the second step, 
the pre-miRNA is cleaved in the cytoplasm by Dicer into ~22 nucleotides mature miRNA, 
which  incorporates  as  single-stranded  RNA  into  the  RNA-induced  silencing  complex 
(RISC).  This  complex  directs the miRNA  to  the  target  mRNAs,  which  leads either  to 
translational repression or degradation of the target transcripts. Processing of mirtrons by 
alternative pathways is depicted. miRNAs-dependent repression of gene expression occurs 
in P-bodies which are also depicted. miRNAs are relocalized to the nucleus, where they 
may regulate transcription or splicing of transcripts (dotted line). Exosomal shuttle RNA is 
also represented as budding vesicles containing miRNAs. 
 
4. microRNAs and Cancer: oncomiRs 
Recent reports have revealed that deregulation of miRNAs expression is common in human cancer 
and correlates with initiation and progression of tumors. Deregulation of these miRNAs, denominated 
as oncomiRs, is associated with genetic or epigenetic alterations, including deletion, amplification, 
point mutation and aberrant DNA methylation. miRNAs can act as oncogenes or tumor suppressors to Int. J. Mol. Sci. 2012, 13  1354 
 
inhibit the expression of cancer-related target genes and to promote or suppress tumorigenesis [5]. 
Those miRNAs whose expression is increased in tumors may be considered as oncogenes. These oncogene 
miRNAs usually promote tumor development by inhibiting tumor suppressor genes and/or genes that 
control cell differentiation or apoptosis [37]. 
In contrast, the expression of some miRNAs is decreased in cancer cells, thus they are considered as 
tumor suppressor genes. Tumor suppressor miRNAs usually prevent tumor development by inhibiting 
oncogenes  and/or  genes  that  control  cell  differentiation  or  apoptosis  [37].  The  identification  of 
deregulated  miRNAs  in  cancer  and  their  respective  targets  may  provide  potential  diagnostic  and 
prognostic tumor biomarkers and represents new therapeutic targets for cancer therapy. In addition, 
large high-throughput studies in patients revealed that miRNA profiling has the potential to classify 
tumors and predict patient outcome with high accuracy [38]. Notably, about half of the annotated 
human miRNAs map within fragile regions of chromosomes, which are areas of the genome that are 
associated with various human cancers [39]. The initial evidence for the involvement of miRNAs in 
cancers came from a molecular study characterizing the 13q14 deletion in human chronic lymphocytic 
leukemia (CLL) [40], where they observed that two miRNAs, miR-15a and miR-16a, are located on 
chromosome 13q14, a region deleted in more than half of B cell chronic lymphocytic leukemia cases, 
which  were  either  absent  or  down-regulated  in  the  majority  of  CLL  patients.  Components  of  the 
miRNA machinery have also been implicated in tumorigenesis. Expression of Dicer has been shown to 
be  down-regulated  in  lung  cancer  which  was  associated  with  poor  prognosis  [41].  Low  levels  of 
Drosha expression were significantly associated with advanced tumor stage in ovarian cancer [42]. 
Argonaute  genes,  AGO3,  AGO1  and  AGO4,  which  are  clustered  on  chromosome  1  
(1p34–35), were frequently deleted in Wilms tumors of the kidney and have also been associated with 
neuroectodermal tumors [43,44]. AGO1 was highly expressed in the developing lung and kidney and it 
was notably increased in renal tumors that lack the Wilms-tumor suppressor gene, WT1. 
In summary, emerging evidence suggests that miRNAs play important roles in human cancers. 
Some miRNAs may be directly involved in cancer development by controlling cell differentiation and 
apoptosis,  while  others  may  be  involved  in  cancers  by  targeting  cancer  oncogenes  and/or  tumor 
suppressors.  Next,  we  will  discuss  the  roles  of  miRNAs  in  metastasis,  the  more  deadly  hallmark  
in cancer. 
5. MestastamiRs: microRNAs Regulating Metastasis 
To successfully metastasize, a tumor cell must complete a complex set of processes, including 
invasion, survival and arrest in the circulatory system, and colonization of foreign organs [45]. Despite 
great  advancements  in  knowledge  of  metastasis  biology,  the  molecular  mechanisms  are  still  not 
completely understood. Remarkably, a regulatory role for miRNAs in metastasis has been established, 
thus they have been denominated metastamiRs, as they have pro- and anti-metastatic effects. The term 
metastamiRs was recently introduced by Welch and colleagues to refer to those regulatory miRNAs 
which promote or suppress various steps in migration and metastasis of cancer cells [46]. It seems that 
these  metastasis-associated  miRNAs  do  not  influence  primary  tumor  either  in  development  or 
initiation steps of tumorigenesis, but they regulate key steps in the metastatic program and processes, 
such as EMT, apoptosis, and angiogenesis. Most commonly, metastamiRs promoting cell migration Int. J. Mol. Sci. 2012, 13  1355 
 
and  invasion  have  been  described.  Because  of  availability  of  robust  metastasis  models,  the  vast 
majority of these metastamirs have been identified in breast and/or mammary tumor cell lines. Next, 
we  review  the  identified  miRNAs  which  have  a  prominent  role  in  metastasis  from  a  number  of  
human cancers. 
5.1. microRNAs in Breast Cancer Metastasis 
The relevant role of miRNAs in breast cancer metastasis was established in seminal papers [47–49]. 
It was previously known that miR-10b was down-regulated in most breast cancers in comparison with 
normal mammary tissues, whereas it was highly expressed in about 50% of metastatic tumors. In 2007, 
Ma,  et  al.  from  Robert  Weinberg’s  group  evidenced  that  up-regulation  of  miR-10b  suppressed 
homeobox  D10  (HOXD10)  expression,  allowing  the  activation  of  pro-metastatic  gene  RHOC  and 
initiation of breast cancer invasion and metastasis [47]. Authors showed that miR-10b was 50-fold 
overexpressed in metastatic MDA-MB-231 cell line, in comparison with tumorigenic non-metastatic 
MCF7 cells. They also demonstrated that ectopic expression of miR-10b had no effect on proliferation 
in vitro, but did result in an increase in migration and invasion properties in two different human breast 
cell lines. In contrast, silencing of miR-10b using antisense inhibitor oligonucleotides led to a 10-fold 
reduction of the invasive properties from transfected cells. Importantly, overexpression of miR-10b in 
non-metastatic tumorigenic cell  lines  promoted robust  invasion, and  lung distant micro-metastases  
in vivo. In addition, miR-10b-overexpressing tumors exhibited high levels of cell proliferation and they 
were highly vascularized. Then, Ma and coworkers showed that TWIST1, a metastasis promoting 
transcription factor [50] specifically binds to the putative promoter of  mir-10b gene activating its 
expression. Moreover, this induced the translation inhibition of homeobox HOXD10 transcription, 
resulting  in  an  increased  expression  of  the  prometastatic  gene  RHOC  (Ras  homolog  gene  family 
member  C).  HOXD10  is  a  type  I  homeobox  transcription  factor  that  maintains  a  differentiated 
phenotype  in  epithelial  cells  and  is  essential  for  morphogenesis  and  differentiation  control  [51]. 
Notably,  HOXD10  expression  was  found  lost  in  breast  tumors  showing  increasing  degrees  of 
malignancy [52]. RHOC is a signaling GTPase-protein involved in metastasis that is repressed by 
HOXD10. Ma and coworkers showed that reduction in RHOC expression by small interfering RNA 
caused repression of miR-10b induced cell migration and invasion, which indicates that RHOC is a 
downstream effector of miR-10b. Besides, it was recently reported that systemic antagomirs-based 
therapeutic silencing of miR-10b in tumor-bearing mice suppressed breast cancer metastasis. Silencing 
of miR-10b significantly decreases miR-10b levels and increases the levels of its target HOXD10 [53]. 
The second hallmark report [48] established that miR-373 and miR-520c can also promote tumor 
invasion and metastasis by regulating the cell-surface glycoprotein encoding gene CD44 (cell surface 
receptor for hyaluronan). In breast cancer cells, the metastatic cell state is strongly correlated to EMT 
and the CD44+/CD24− stem cell phenotype. Cell lines with high CD44+/CD24− cell numbers are 
basal/mesenchymal or myoepithelial types and are more invasive than other cell lines [54]. In order to 
identify new potential metastasis-promoting miRNAs, Huang, et al. from Agami’s group set up a 
genetic  screen  using  the  non-metastatic  MCF7  cell  line,  and  found  that  miR-373  and  miR-520c 
stimulated  cell  migration  and  invasion  in  vitro  and  in  vivo.  Similarly  to  miR-10b,  miR-373  and  
miR-520c did not affect cell proliferation. Previously, the same group identified miR-373 as a potential Int. J. Mol. Sci. 2012, 13  1356 
 
oncogene  in  testicular  germ-cell  tumors  where  it  suppressed  the  oncogene-induced  p53  pathway, 
which cooperates with oncogenic RAS to promote cellular transformation [55]. Interestingly, Huang 
and  coworkers  found  that  miR-373  and  miR-520c  “seed”  sequences  were  similar  and  both  target  
CD44 messenger RNA. Moreover, enhanced expression of a CD44 gene that was unresponsive to  
miR-373/miR-520c  inhibited  the  migratory  activity  of  MCF7  cells  overexpressing  miR-373  and  
miR-520c. Finally, they analyzed the miR-373 expression in breast cancer clinical specimens and 
found a significant up-regulation of miR-373 in 11 matched normal/tumor samples, which inversely 
correlated with CD44 expression, in particular in tumors exhibiting lymph node metastasis.  
The third outstanding study reports the identification of new miRNAs involved in breast cancer 
metastasis [49]. The team led by Joan Massague found that miR-335, miR-126, and miR-206 are 
metastasis-suppressors.  Authors  performed  array-based  miRNA  profiling  in  MDA-MB-231  breast 
cancer cell derivatives highly metastatic to bone and lung, and found a signature of six genes (miR-335, 
miR-126, miR-206, miR-122a, miR-199a*, and miR-489) whose expression was highly decreased in 
metastatic cells. Restoring the expression of miR-335, miR-126 or miR-206 in LM2 cells decreased 
the lung colonizing activity of these cells by more than fivefold. Interestingly, miR-126 restoration 
reduced overall tumor growth and proliferation, whereas miR-335 inhibited metastatic cell invasion. In 
addition, low expression of miR-335 or miR-126 in primary tumors from patients was associated with 
poor distal metastasis-free survival. To obtain more insights about the miR-335 loss consequences, 
authors  transfected  MDA-MB-231  cells  with  an  anti-miRNA  antagomir  targeting  either  miR-335, 
miR-199a* or a control sequence, and found that inhibition of miR-335 enhanced the lung-colonizing 
ability of cells. Then, they profiled LM2 cells overexpressing miR-335 and identified 756 genes whose 
expression  was  decreased  when  compared  with  control  LM2  cells,  including  genes  previously 
implicated  in  extracellular  matrix  and  cytoskeleton  control  (type  1  collagen  COL1A1)  and  signal 
transduction (receptor-type tyrosine protein phosphatase PTPRN2, c-Mer tyrosine kinase (MERTK) 21 
and phospholipase PLCB1), as well as in cell migration, such as the tenascin C (TNC), an extracellular 
matrix glycoprotein of stem cells niches [56] and the SRY-box containing transcription factor SOX4 [57]. 
These experimental evidences indicated that miR-335 suppresses metastasis and migration by targeting 
the  progenitor  cell  transcription  factor  SOX4  and  TNC  messenger  RNAs.  Consequently,  loss  of  
miR-335 leads to the activation of SRY-box containing SOX4 and TNC, which are responsible for the 
acquisition of metastatic properties. Notably, knockdown of SOX4 and TNC using RNA interference 
diminished in vitro invasive ability and in vivo metastatic potential, evidencing that both genes are key 
effectors of metastasis [49]. Recently, Tavazoie’s group reported that miR-126 regulates endothelial 
cell recruitment to metastatic breast cancer cells, in vitro and in vivo. They evidenced that miR-126 
suppresses  metastatic  endothelial  recruitment,  metastatic  angiogenesis  and  metastatic  colonization 
through coordinate targeting of insulin-like growth factor binding protein 2 (IGFBP2), PITPNC1 and 
c-Mer tyrosine kinase (MERTK) receptor genes [58]. 
In addition, others miRNAs with prominent roles in breast cancer metastasis have been reported. 
miR-146a and b inhibited invasion and migration of breast cancer cells by down-regulating NFκB 
through IRAK1 and TRAF6 targeting [59]. These studies were extended in vivo by showing both  
miR-146a and b suppressed metastasis that may involve targeting of EGF receptor or ROCK1 [60] 
both of which are involved in promoting invasion and metastasis. Hurst and coworkers showed that 
breast cancer metastasis suppressor 1 (BRMS1), a protein that regulates expression of multiple genes Int. J. Mol. Sci. 2012, 13  1357 
 
leading to suppression of metastasis, significantly up-regulates miR-146a and miR-146b in metastatic 
breast cancer cells. Transduction of miR-146a or miR-146b into MDA-MB-231 down-regulated expression 
of  epidermal  growth  factor  receptor,  inhibited  invasion  and  migration  in  vitro,  and  suppressed 
experimental lung metastasis [61]. In addition, it was reported that miR-31 inhibited multiple steps of 
metastasis including invasion, anoikis, and colonization leading to almost complete reduction in lung 
metastasis [62]. Clinically, miR-31 levels were lower in breast cancer patients with metastasis. In 
another study, it was reported that suppression of miR-21 in metastatic MDA-MB-231 breast cancer 
cells  significantly  reduced  invasion  and  lung  metastasis,  by  targeting  programmed  cell  death  4 
(PDCD4)  and  maspin,  both  of  which  have  been  implicated  in  invasion  and  metastasis.  Li  and 
coworkers reported that down-regulation of miR-193b contributes to enhance urokinase-type plasminogen 
activator expression and tumor progression and invasion in human breast cancer [63]. By profiling of 
primary breast tumors, tumor associated normal tissue and breast cancer cell lines using RQ-PCR, as 
well as functional assays, it was demonstrated that miR-183 targets ezrin and may play a central role in 
the regulation of migration and metastasis in breast cancer [64]. Sachdeva and Mo reported that miR-
145  suppresses  cell  invasion  and  metastasis  by  directly  targeting  the  metastatic  gene  mucin  1. 
Moreover, they showed that suppression of MUC1 by miR-145 causes a reduction of β-catenin as well 
as the oncogenic cadherin 11 [65]. Yu and colleagues demonstrated a unique mechanism of how the 
altered microRNA17/20 expression regulates cellular secretion and tumor microenvironment to control 
migration and invasion of neighboring cells in breast cancer. They showed that miRNA17/20 directly 
represses IL-8 by targeting its 3′ UTR, and inhibits cytokeratin 8 via the cell cycle control protein 
cyclin D1 [66]. In addition, miR-9, which is up-regulated in breast cancer cells, directly targets CDH1, 
the  E-cadherin-encoding  messenger  RNA,  leading  to  increased  cell  motility  and  invasiveness  [67]. 
Remarkably,  it  was  reported  that  overexpression  of  miR-200,  which  promotes  a  mesenchymal  to 
epithelial cell transition by inhibiting Zeb2 expression, unexpectedly enhances macroscopic metastases 
in  mouse  breast  cancer  cell  lines.  These  findings  were  surprising  since  the  miR-200  family  was 
previously shown to promote epithelial characteristics by inhibiting the transcriptional repressor Zeb2 
and thereby enhancing E-cadherin expression [68]. In another study, Vetter and coworkers showed that 
miR-661  expression  in  MCF7  breast  cancer  cells  conditionally  overexpressing  the  EMT  master 
regulator SNAI1 contributes to breast cancer cell invasion by targeting cell-cell adhesion Nectin-1 and 
the lipid transferase StarD10 messengers [69]. Yong Li and coworkers found that miR-196 inhibited 
the  expression  of  HOXC8  transcription  factor,  which  suppressed  cell  migration  and  metastasis. 
Importantly, unlike other metastasis-associated miRNAs that have been described, the expression of 
miR-196 was not correlated with breast cancer cell migration or the metastatic status of clinical breast 
tumor  specimens.  Instead,  they  detected  a  correlation  between  the  ratio  of  miR-196  to  HOXC8 
expression and the migratory behavior of breast cancer cell lines, as well as the metastatic status of 
clinical samples [70]. 
5.2. MetastamiRs in Lung Cancer 
Lung cancer is the leading cause of cancer-related mortality in men and women worldwide. The 
most common lung cancer subtype is non-small cell lung cancer (NSCLC). 75% of the lung cancer 
patients present local and/or distant metastases with median survival by 3 to 5 months [71]. Several Int. J. Mol. Sci. 2012, 13  1358 
 
studies have documented the implications of miRNAs in nearly every carcinogenesis process of lung 
cancer.  Overexpression  or  suppression  of  specific  miRNAs  can  regulate  the  biological  alterations 
during lung carcinogenesis, such as development and growth tumor, resistance to anti-cancer drug, 
apoptosis, as well as invasion and metastasis. Investigations of miRNAs targets and pathways that they 
regulate, which include known tumor suppressors and oncogenes, can explain their effects to either 
promote or inhibit metastatic potential in lung cancer [72]. EGFR is one of the most common mutated 
genes in NSCLC, which has been used as a clinical predictor of therapeutic response. EGFR dependent 
signaling pathways are responsible for regulation of many biological features of NSCLC, including 
metastases [73]. MiR-125a-5p was reported to inhibit migration and invasion of lung cancer cells by 
regulating the expression of several downstream genes of EGFR signaling [74]. Furthermore, miRNA 
profiling  has  linked  miR-125a-5p  expression  to  metastatic  tumor  features  and  lung  cancer  patient 
outcome,  thus  having  a  potential  diagnostic  and  prognostic  impact  [75].  Down-regulation  of  
miR-125a-3p  and  miR-125a-5p  in  NSCLC  could  predict  a  more  aggressive  clinical  course  by 
promoting tumor invasion and lymph node metastasis [76]. 
miR-183 was identified as a negative regulator of lung cancer metastasis from screening with a 
miRNA array. Expression level of miR-183 was demonstrated to reversely correlate with the metastatic 
potential of lung cancer cells by targeting VIL2-coding protein ezrin and regulating the expression of 
other genes involved in migration and invasion. Ezrin, which was confirmed by luciferase reporter 
gene assay, has a role in controlling the actin cytoskeleton, cell adhesion and motility [77]. Sarver and 
collaborators found that the expression levels of miR-183, as well as miR-96 and miR-182, were 
higher in A549 and 95D metastatic lung cancer cells than in H1299 and 95C non-metastatic cells, 
respectively, suggesting that the miR-183 family might participate in tumor metastasis [78]. Moreover, 
members  of  the  miR-183  family  were  highly  expressed  in  lung  cancer  primary  tissues  and  sera. 
Overexpression of miR-182 and miR-183 in NSCLC tumors was strongly associated with metastasis. 
Notably,  miR-183  was associated  to  lymph  node  metastasis,  invasion  of  the lung  membrane,  and 
advanced  clinical  stage  of  NSCLC,  while  overexpression  of  miR-182  was  positively  related  to 
invasion of the lung membrane and tumor size >3 cm in NSCLC [79]. 
miR-126 that was previously described as a potential metastasis suppressor miRNA in human breast 
cancer [49] was also found down-regulated in lung cancer [80]. Experimentally, overexpression of 
miR-126 in lung cancer cell line resulted in a decrease of Crk protein that belongs to the family of 
adaptor proteins involved in intracellular signal pathways altering cell adhesion, proliferation, and 
migration. Elevated levels of Crk expression have been implicated in lung cancer and are associated 
with increased tumor invasiveness, which provided clinical relevance to these findings. miR-126 can 
decrease adhesion, migratory and invasive capacity of lung cancer cell lines through posttranscriptional 
silencing Crk [81]. 
As an early step during metastasis, EMT also seems to be tightly regulated by miRNAs, mainly the 
miR-200 family [82]. miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting 
Flt1/VEGFR1 in a mouse model [83], while miR-221 and 222 enhance cellular migration through 
activation  of  the  AKT  pathway  [84].  miRNAs  expression  in  tumoral  tissues,  serum  and  blood  in 
relation with their metastatic potential might have a clinical impact. The serum level of SERPINB5, 
TPM1, RECK, TIMP3 miRNAs could be identified as an indicator for metastatic NSCLCs and may be 
applied clinically in combination with other lung cancer-specific miRNAs, such as miR-21, miR-210, Int. J. Mol. Sci. 2012, 13  1359 
 
and miR-486-5p in the future [85]. Overexpression of miR-21 further stimulates invasion, intravasation 
and metastasis through targeting of SERPINB5, TPM1, RECK, and TIMP3 genes [86,87]. 
Very recently, Wang and coworkers analyzed miRNA expression profiles in NSCLC and identified 
40 differentially expressed miRNAs. miR-451 was the most down-regulated in NSCLC tissues [88]. 
Moreover, low expression level of miR-451 was found to be significantly associated with NSCLC 
tumor  differentiation,  pathological  stage,  lymph  node  metastasis,  and  shorter  overall  survival  of 
patients. Data also indicated that miR-451 regulates survival of NSCLC cells partially through the 
down-regulation of RAB14, which suggested that targeting miR-451/RAB14 interaction might serve 
as a novel therapeutic application to treat NSCLC patients [88]. 
Epigenetic  regulation  is  a  mechanism  to  inhibit  the  expression  of  miRNAs,  Lujambio,  et  al. 
reported that methylation of miR-9-3 was associated with lymph node metastasis. Among the miRNAs 
that were reactivated upon drug treatment based on demethylation, miR-148a, miR-34b/c, and miR-9 
were found to undergo specific hypermethylation-associated silencing in cancer cells compared with 
normal tissues [89]. The reintroduction of miR-148a and miR-34b/c in cancer cells with epigenetic 
inactivation  inhibited  cell  motility,  reduced  tumor  growth,  and  inhibited  metastasis  formation  in 
xenograft models, with an associated down-regulation of the miRNA oncogenic target genes, such as 
C-MYC, E2F3, CDK6, and TGIF2. Particularly, the involvement of miR-148a, miR-34b/c, and miR-9 
hyper-methylation in metastasis formation was also suggested in human primary malignancies because it 
was significantly associated with the appearance of lymph node metastasis. These findings indicated 
that  DNA  methylation-associated  silencing  of  tumor  suppressor  miRNAs  contributes  to  the 
development of human cancer metastasis. 
Identification of a metastatic miRNA signature offers an exciting new insight into the molecular 
mechanisms  underlying  cancer  metastasis  and  it  may  represent  a  novel  diagnostic  tool  in  the 
characterization of metastatic cancer gene targets. Baffa and collaborators identified a global miRNA 
expression signature that can distinguish primary colon, bladder, breast, and lung cancers from their 
corresponding  metastasis  to  lymph  nodes,  confirming  a  direct  involvement  of  miRNAs  in  cancer 
metastasis [90]. Authors performed a miRNA microarray analysis and they identified a metastatic 
cancer  miRNA  signature  comprising  15  overexpressed  and  17  repressed  miRNAs.  Up-regulated 
miRNAs in NSCLC included miR-142-5p, miR-148b, miR-148a, miR-369-3p, miR-215, miR-152 and 
miR-155, whereas down-regulated miRNAs were miR-373 and miR-138-I. Some of these miRNAs 
have  a  well-characterized  association  with  cancer  progression,  e.g.,  miR-10b,  miR-21,  miR-30a,  
miR-30e, miR-125b, miR-141, miR-200b, miR-200c, and miR-205 [90]. 
Almost 25% of patients with NSCLC will have brain metastasis. Analysis of expression profiles of 
miRNAs obtained from lung tumors samples that are able to develop brain metastasis revealed that 
miR-328 was associated with higher risk for developing brain metastasis. In vitro studies using lung 
cancer cells showed that miR-328 enhances cell migration, which confirmed the relevance of miRNAs 
in NSCLC metastatic process [91]. 
5.3. MetastamiRs in Prostate Cancer 
Prostate cancer is the second more lethal cancer type in men in America [71]. Patients with prostate 
tumors often present multifocal localized disease that can have a long indolent period of 10–15 years Int. J. Mol. Sci. 2012, 13  1360 
 
before it progresses to metastatic disease. The principal metastasis site for prostate tumors is bone; 
once it has progressed to metastasis, the disease is currently incurable, since metastatic cells are highly 
resistant to conventional therapies. This suggested that prostate tumor cells have a latency period more 
extensive than other cancer types for which the latency period between primary and metastatic disease 
is relatively short. The involvement of miRNAs in human prostate cancer has been well documented 
and some aberrantly expressed miRNAs have been discovered in cell lines, animal models and clinical 
tissues from prostate tumors. These miRNAs may play critical roles in the development and progression 
of prostate cancer, including metastatic events [92]. MiR-21 is one of the more extensively studied 
miRNAs in many tumors types including prostate cancer, producing a more marked effect on tumor 
metastasis [93]. The level of miR-21 expression significantly correlates with advanced clinical stage, 
metastasis and poor prognosis in these tumors. Studies using prostate cancer cells have shown that 
miR-21 targets myristoylated alanine rich protein kinase c substrate (MARCKS), which is involved in 
cellular processes, such as cell adhesion and cell motility through regulation of the actin cytoskeleton. 
Notably, cell proliferation was not affected, which suggested that molecules that are regulated by  
miR-21 might be important to metastatic process in prostate cells [94]. Recently, Watahiki, et al. 
obtained miRNA profiles through massively parallel DNA sequencing from a transplantable metastatic 
compared  with  non-metastatic  prostate  cancer  xenograft  line,  both  derived  via  subrenal  capsule 
grafting,  and  from  one  patient’s  primary  cancer  tissue.  Differentially  expressed  known  and  novel 
miRNAs were detected that might have specific roles in the metastasis of prostate cancer. Predicted 
target genes of these miRNAs were related to cancer and metastasis, confirming their potential role in 
these events in prostate cancer cells [95]. Some studies suggested that miR-205 specifically suppresses 
the expression of ErbB3 and VEGF-A, which are highly related to metastasis and invasion. Apparently, 
miR-205 interacts with its putative binding site at the 3′-UTR of both genes [96]. Gandellini and 
coworkers have suggested that miR-205 is overexpressed in normal prostate tissue and RWPE-1 cells, 
whereas it is almost undetectable in both androgen-dependent and androgen-independent prostate cancer 
cells.  Moreover,  overexpression  of  miR-205  in  prostate  cancer  cells  promotes  up-regulation  of  
E-cadherin and reduction of cell locomotion and invasion, suggesting a relation with EMT. Target 
prediction analysis indicates that miR-205 could regulate N-chimaerin, ErbB3, E2F1, E2F5, ZEB2, 
and protein kinase-C epsilon expression [97]. 
Another report demonstrated that miR-101 plays a major role in EMT through enhancement of a 
histone methyl transferase Zeste homolog (EZH2) whose expression was found elevated in a subset of 
aggressive, clinically localized prostate cancers and almost all metastatic prostate cancers. miR-101 
locus  is  lost  in  metastatic  prostate  cancer,  which  leads  to  up-regulation  of  EZH2,  indicating  that 
miRNA-101 acts as a EZH2 repressor [98]. Up-regulation of EZH2 through miR-101 induces the 
concomitant deregulation of epigenetic pathways and results in cancer progression [99]. 
Recently, Peng and colleagues reported that the expression of five miRNAs, namely miRs-508-5p,  
-145, -143, -33a and -100, was significantly decreased in bone metastasis when compared with primary 
tumor prostate. Two miRNAs, miRs-143 and -145, were up-regulated, and they were able to repress 
migration and invasion in vitro, tumor development and bone invasion in vivo, as well as EMT of PC-3 
derived from metastatic cells. Since the principal problem arising from prostate cancer is its propensity 
to  metastasize  to  bone,  these  findings  could  be  important  for  the  understanding  of  metastasis  
organ-specific in prostate cancer [100]. Int. J. Mol. Sci. 2012, 13  1361 
 
5.4. MetastamiRs in Colorectal Cancer 
There are currently about 100 miRNAs implicated in colorectal cancer (CRC) alone [101]. The most 
up-regulated miRNAs are: miR-21, miR 17-92 cluster, miR-135a/b, miR-471 and miR-675, whereas 
miR-143, miR-14, let-7 and  miR-101 showed a  decreased expression in  CRC. All  of them  affect 
different target genes and have been experimentally validated. The main targets of these miRNAs 
include transcription factors like c-MYC, STAT, OCT4, SOX, E2F1, ZEB1, ZEB2 and NFIB, some 
kinases, such as ERK and YES1, and other proteins involved in matrix metalloproteinasas regulation 
like RECK and TIMP3 that serve as metastasis suppressors [102]. The extracellular matrix remodeling 
is one of the necessary conditions for tumor growth, invasiveness and metastasis, and it has been 
reported that up-regulation of miR-21 in CRC cells increases their migratory and invasive abilities. 
The mechanism is not well elucidated but, it could be through regulation of RECK and TIMP3 genes 
like in glioblastoma model. Then miR-21 could be implicated in extracellular matrix breakdown [103,104]. 
Using a mouse model of colon cancer, Dews, et al. demonstrated that the angiogenic activity of  
c-MYC is due at least in part to downstream activation of the miR-17-92 cluster. The anti-angiogenic 
factors,  thrombospondin-1  (TSP1)  and  connective  tissue  growth  factor  (CTGF),  are  negatively 
regulated by these miRNAs, which are potently induced by c-MYC in this model. Robust vascularization 
of tumors can be induced by expression of either c-MYC or the miR-17-92 cluster [105]. 
5.5. MetastamiRs in Gastric Cancer 
Human gastric cancer (GC) is an aggressive and lethal malignancy and is one of the most frequent 
around the world. Recent studies have shown an association of miRNAs expression and different 
malignancies but their prognostic role in gastric cancer is poorly understood. The first report about the 
association between miRNAs and gastric cancer was published in 2009 by Guo and collaborators [106]. 
These authors showed that miRNAs 20-b, miR-20a, miR-17, miR-21, miR-106a, miR-18a, mir-21, 
miR106b, mir-18b, miR-421, miR-340, miR-19a and miR-658 were highly expressed in GC. Among 
them, miR-340*, miR-421 and miR-658 were first found highly expressed in cancer cells. In addition, 
the expression of some target genes, such as Rb and PTEN, was predicted in GC tissues. More recently, 
Brenner and collaborators analyzed and compared miRNAs profiles between primary tumor of patients 
with  recurrent  and  non-recurrent  GC  and  reported  that  three  miRNAs  (miR-451,  miR-199a-3p  and 
miR195) were differentially expressed in tumors from patients with good prognosis in comparison 
with patients with bad prognosis [107]. Of these, miR-451 had the strongest prognostic impact. On the 
other  hand,  the  overexpression  of  miR-27  in  GC  tissues  has  been  related  to  increased  levels  of 
epithelial-mesenchymal  transition-associated  genes  ZEB1,  ZEB2,  slug  and  vimentin,  as  well  as  to 
decreased E-cadherin levels. As we mentioned above, epithelial-mesenchymal transition (EMT) is a 
key  step  toward  cancer  metastasis.  These  data  indicated  that  miR-27  promotes  gastric  cancer 
metastasis, activating MET and Wnt/b-catenin pathways, suggesting a potential application of miR-27 
for gastric cancer therapy [108]. 
Liang  and coworkers  demonstrated that  overexpression of let-7f in  gastric cancer could inhibit 
invasion and migration of GC cells through direct targeting of the tumor metastasis-associated gene 
MYH9 [109]. These authors used qRT-PCR experiments to evidence the low expression levels of  Int. J. Mol. Sci. 2012, 13  1362 
 
let-7f in metastatic gastric cancer tissues and cell lines that are potentially highly metastatic. Using 
xenograft models of GC in nude mice, they confirmed that let-7f could inhibit gastric cancer metastasis 
in  vivo  after  transfection  by  the  lentivirus  pGCsil-GFP-  let-7f.  miR-148a  functions  as  a  tumor 
metastasis suppressor in GC, and its down-regulation contributes to GC lymph-node metastasis and 
progression. The authors examined miR-148a levels in 90 gastric cancer samples by qRT-PCR and 
showed clinicopathological significance with miR-148a expression. They also found that GC cells 
transfected with miRNA-148a had reduced migration and invasion capacities in vitro and metastasis 
ability in vivo. In addition, overexpression of miR-148a in GC cells reduces mRNA and protein levels 
of ROCK1, whereas miR-148a silencing significantly increased ROCK1 expression [110]. 
Deregulation of others miRNAs, such as miR-622, miR-107, miR-221, and miR-222, has been 
described  in  GC.  MiR-622  expression  was  down-regulated  in  gastric  cancer  whereas  ectopic 
expression of miR-622 promoted invasion, tumorigenesis and metastasis of GC cells both in vitro and 
in  vivo.  A  luciferase  reporter  assay  showed  the  effect  of  miR-622  on  inhibitor  of  growth  family, 
member 1 (ING1) expression [111]. The expression of miR-107 was found inversely correlated with 
CDK6  expression in  GC cell lines. The authors argued  that miR-107 could significantly  suppress 
CDK6 3′-UTR luciferase reporter activity. Ectopic expression of miR-107 reduced both mRNA and 
protein expression levels of CDK6. Moreover, it inhibited proliferation, induced G1 cell cycle arrest, 
and blocked invasion of the gastric cancer cells [112]. DICER1 and PTEN genes have been identified 
as target genes for miR-107 and miR-222, respectively [113,114]. miR-101 was found down-regulated 
in  gastric  cancer  tissues,  and  its  ectopic  expression  significantly  inhibited  cellular  proliferation, 
migration, and invasion of GC cells but its gene target has not been identified yet [115]. 
Finally,  an  interesting  study  published  by  Wu  and  colleagues  reported  that  the  expression  of  
thirty-eight miRNAs in gastric cancer tissues was significantly different from that observed in paired 
normal  tissues,  using  stem-loop  real-time  reverse  transcription-polymerase  chain  reaction  [116]. 
Among them, 31 miRNAs were found to be overexpressed in cancer tissues and one miRNA was ≥1.5 
fold  down-regulated.  Particularly,  the  authors  concluded  that  miR-212  and  miR-195  could  be 
independent biomarkers to predict gastric cancer metastasis to lymph node. 
5.6. MetastamiRs in Head and Neck Cancer 
Head and neck cancer includes biologically similar tumors of the nasal cavities, paranasal sinuses, 
oral cavity (inner lip, tongue, floor of mouth, gingivae, and hard palate), nasopharynx, oropharynx, 
hypopharynx, and larynx. Almost all these tumors are squamous cell carcinomas (SCC) arising from 
mucosal surfaces. Head and neck squamous cell carcinoma (HNSCC) is one of the most common 
cancers worldwide, with about 500,000 new cases each year [71]. HNSCC usually are asymptomatic 
until they spread to the lymph nodes of the neck, which often represents the first diagnosis element at a 
late stage of the disease that is characterized by invasion and metastasis events in the head and neck 
area. Prognosis remains poor for most HNSCC patients, with only five years survival. 
By  comparison  of  miRNA  expression  profiles  from  six  paired  HNSCC  cell  lines  (UM1/UM2, 
1386Tu/1386Ln  and  686Tu/686Ln)  with  different  metastatic  potential,  Liu  and  colleagues  [117] 
evidenced a set of differentially expressed miRNAs. Some of them have been previously implicated in 
tumorigenesis and metastasis, while the role of others in tumorigenesis is not clear. Particularly, lower Int. J. Mol. Sci. 2012, 13  1363 
 
miR-138  levels  were  consistently  observed  in  all  highly  invasive  cell  lines.  Down-regulation  of  
miR-138 has been previously observed in tongue squamous cell carcinoma (TSCC) [118] and thyroid 
carcinoma [119]. Ectopic transfection of miR-138 mimic suppressed cell invasion and led to cell cycle 
arrest  and  apoptosis.  In  contrast,  knockdown  of  miR-138  enhanced  cell  invasion  and  suppressed 
apoptosis. Two putative genes for miR-138 precursors have been located on chromosome 3p21.33 and 
16q13, respectively, in human genome. Notably, loss of heterozygosity at both chromosome loci is a 
frequent event that has been associated to HNSCC progression and metastasis [120–122], which could 
be due to reduced levels of miR-138. 
Using the same TSCC UM1/UM2 cell lines and microarray assays, another group reported the 
down-regulation  of  23  miRNAs  and  the  up-regulation  of  22  miRNAs  in  highly  metastatic  UM1  
cells [123]. Down-regulated miRNAs included miR-222 that has been previously suggested to play a 
role in tumorigenesis by targeting cell cycle inhibitor p27, which leads to deregulation of cell cycle 
control in several cancer types [124,125]. Transfection of UM1 cells with the hsa-miR-222 mimic did 
not modify apoptosis or cell cycle, but led to a significant decrease in cell invasion (p < 0.05). In 
addition, a targeting site for hsa-miR-222 was identified in the 3′-UTR of the matrix metalloproteinase 1 
(MMP1) and manganese superoxide dismutase 2 (SOD2) mRNA sequences by in silico analysis and 
confirmed by luciferase reporter gene assays. Ectopic transfection of hsa-miR-222 induced a decrease 
in MMP1 and SOD2 levels in UM1 cells. Furthermore, MMP1 and SOD2 independent knockdown by 
siRNA evidenced that the reduced MMP1 and SOD2 levels are associated with reduced cell invasion, 
which suggested that hsa-miR-222 regulates TSCC invasion by targeting MMP1 and SOD2 mRNA. In 
addition,  SOD2  knockdown  led  to  the  down-regulation  of  MMP1  expression,  in  agreement  with 
previous observations that SOD2-dependent production of H2O2 regulates expression of MMP family 
members (including MMP1) and contributes to cancer cell metastasis [126–128]. 
The  study  of  31  laser-microdissected  nasopharyngeal  carcinomas  (NPC)  and  10  healthy 
surrounding  nasopharyngeal  epithelial  cells  through  highly  sensitive  microarray-based  procedures 
evidenced  the  differential  expression  of  miR-29c  (>5-fold)  [129].  Computational  approaches  and 
analysis  of mRNA  expression  profiling  data  of  the  same  specimens,  allowed  the  identification  of 
putative miR-29c target genes, which are involved in extracellular matrix synthesis or its functions, 
including seven collagens and laminin γ1, that are associated with increased invasiveness in culture 
and increased metastasis in animal models and multiple human solid tumors as well as fibrillin and 
secreted protein, acidic, cysteine-rich (SPARC). Interestingly, the >5-fold down-regulation of mir-29c 
level correlated with 2- to 6-fold increase of target mRNAs in NPC tumors, which could facilitate 
rapid matrix generation and renewal during tumor growth and the acquisition of tumor motility. In 
cultured  cells,  introduction  of  miR-29c  led  to  a  reduced  transcription  of  these  genes.  Moreover, 
luciferase reporter gene assays confirmed that miR-29c interacts with their 3′ UTR [130–135]. 
miR-10b  has  been  involved  in  breast  cancer  invasion  and  metastasis  [39].  Interestingly,  its 
expression  can  be  induced  directly  by  the  transcription  factor  Twist,  a  key  molecule  for 
nasopharyngeal carcinoma (NPC) metastasis [136] and the expression of Twist can be induced by 
Latent membrane protein-1 (LMP1) encoded by Epstein-Barr virus (EBV) that is also involved in 
promoting NPC metastasis [137]. Li and coworkers [138] showed that both LMP1 and miR-10b are 
over expressed in metastatic EBV+ human NPC C666-1 cell. The levels of miR-10b were significantly 
reduced  in  LMP1-silent  C666/shLMP  cells,  while  dramatically  elevated  in  LMP1-over-expressing Int. J. Mol. Sci. 2012, 13  1364 
 
C666/LMP  cells,  which  indicated  that  LMP1  expression  was  positively  associated  with  miR-10b 
expression in NPC cells. Interestingly, inhibition of Twist expression by siRNA dramatically reduced 
miR-10b levels in LMP1 expressing cells, but not in the LMP1-silent C666/shLMP and miR-10b over 
expressing C666/shLMP/miR-10b cells. The authors proposed that LMP1 may induce the expression 
of  Twist,  which  in  turn  up-regulates  miR-10b  transcription  in  NPC  cells.  Induction  of  miR-10b 
overexpression in LMP1-silent C666-1 cells promoted significant wound healing and transmembrane 
invasiveness in vitro. More importantly, miR-10b over-expression promoted the metastasis of NPC 
and accelerated the death of tumor-bearing nude mice. 
A recent report [139] showed that metastatic human HNSCC are associated with low levels of 
TAp63,  a  p53  family  member  that  acts  a  tumor  suppressor  gene,  [140].  Metastatic  HNSCC  also 
exhibited reduced levels of Dicer, the endoribonuclease involved in miRNA generation that has been 
shown to function as a haploinsufficient tumor suppressor [141]. TAp63 binds to and transactivates the 
Dicer  promoter,  suggesting  a  role  in  metastasis  through  alteration  of  miRNA  processing.  Indeed,  
miR-130b [142] was down-regulated in metastatic HNSCCs cells lacking TAp63. Based on these data, 
the authors concluded that the participation of TAp63 in tumor and metastasis suppression involves the 
coordinate transcriptional regulation of Dicer and miR-130b [139]. 
Computational  genome-scale  predictive  strategies  were  also  used  to  predict  down-regulated 
miRNAs in HNSCC [143]. The expression of one of these miRNA, miR-204, was highly reduced in 
HNSCC tumors and this was related to the genomic imbalanced 9q21.1–22.3 locus corresponding to 
host gene transient receptor potential melastatin 3 cation channel (TRPM3) that has been associated 
with  genetic  predisposition  for  head  and  neck  cancer  [144].  Predicted  miR-204  targets  that  are  
up-regulated in HNSCC are significantly related through their biological functions, mainly participating 
in  proteolysis,  cell  adhesion,  cell  cycle  regulation  and  cell  proliferation.  Expression  profiling  and 
computational  biological  approaches  confirmed  that  miR-204  suppression  could  up-regulate  genes 
involved in cell cycle and extracellular matrix remodeling associated to cancer metastasis and/or poor 
prognosis. Indeed, miR-204 overexpression is sufficient to suppress cell-matrix interaction, motility 
and invasiveness in vitro, as well as experimental lung colonization of SQ38 HNSCC tumors in vivo, 
demonstrating that it represents a potent suppressor of metastasis. Expression pattern of 19 miR-204 
targets  identified  a  subtype  of  HNSCC  tumors  exhibiting  an  EGFR-pathway  signature  [145]  and 
predicted  earlier  relapse,  which  suggested  a  potentially  important  role  of  miR-204  in  HNSCC 
prognosis. The discovery of molecular networks regulated by microRNAs could be exploited for the 
design of new treatments as an alternative to the single-gene target paradigm. 
5.7. MetastamiRs in Cervical Carcinoma 
Cervical carcinoma (CC) is a leading cause of death among women worldwide, with an estimated 
incidence of 470,000 new cases and 233,000 deaths per year [146]. Epidemiologic and experimental 
studies have identified a causal role of high risk HPV types in cervical carcinogenesis, mainly HPV 16 
and HPV 18 [147]. Persistent viral infection in combination with strong, constitutive expression of E6 
and E7 viral oncogenes is a necessary step for malignant transformation because these proteins interact 
with p53 and pRB proteins leading to their degradation and deregulation of the cell cycle [148,149]. 
Moreover,  E6  and  E7  target  additional  cellular  proteins  and  transcriptional  regulators  [150,151] Int. J. Mol. Sci. 2012, 13  1365 
 
including c-MYC [152], and Skip [153]. Finally, at DNA level, E6 and E7 deregulate cell proliferation 
and induce genetic instability, which promote the accumulation of mutations and aneuploidy [154]. 
HPV oncoproteins play an important role in miRNA expression by means of p53 degradation induced 
by E6 and E7, which induces pRB degradation and subsequently, E2F release from the pRB-e2F 
complex,  which  leads  to  overexpression  of  the  transcription  factor  c-MYC.  c-MYC  induces  the 
expression of the miR-17-92 family [155], a miRNA polycistron also known as oncomir-1 that is up-
regulated  in  a  wide  variety  of  human  tumors  [156,157].  p53  regulates  cellular  miRNAs  by 
transcriptional activation of miR-23a, -26a and 3-4a. On the other hand, p53 decreases expression of 
distinct  miRNA  clusters,  such as miR-106b/miR-93/miR-25, miR-17-15p/18a/19a/20a/19b-1/92-1 and 
miR-106a/18b/20b/19b-2, through an indirect mechanism which involves repression of E2F1 [158]. As 
it can be noted, E6 and E7 viral oncoproteins exert an important role on cervical epithelia miRNA 
expression profiles. 
A few reports have explored the role of potential metastatic or anti-metastatic miRNAs in CC. In 
CC cells, Qiang and colleagues evidenced a marked overexpression of Plexin B1, the receptor for 
Sema4D that has been reported to trigger multiple cellular responses, including metastasis in various 
types of tumor cells. The high Plexin B1 overexpression inversely correlated with miR-214 levels in 
normal  and  tumoral  samples,  which  suggested  that  miR-214  could  have  distinct  roles  during  the 
inhibition of malignant phenotype, including cell cycle induction, migration and metastasis, probably 
mediated by Plexin B1 inhibition [159]. 
Using microarray expression profile to analyze 96 cancer-related miRNAs, Hu and coworkers were 
able to identify ten miRNAs (miR-200a, miR-9, miR-10b, miR-183, miR-204, miR-24, miR-181a, 
miR-193b, miR-146b and miR-10a) related to cervical cancer survival. Notably, functional characterization 
indicated  that  miR-200a  regulates  cell  adhesion  and  cancer  cell  metastasis.  Hu  and  colleagues 
proposed  that  miR-200a  expression  inhibition  during  CC  carcinogenesis  process  could  lead  to 
increased  cancer  cell  motility.  Possible  targets  for  miR-200a  are  ZEB1/2,  TGFB2  AND  EXOC5, 
which are related to the metastatic potential of tumor cells [160]. Finally, Lee and collaborators showed 
that there is a miRNA deregulation in early stage of cervical cancer progression, in comparison with 
normal cervical epithelial tissues; moreover, miR-127 could regulate lymph node metastasis [161]. 
5.8. MetastamiRs in Hepatocellular Carcinoma 
Primary liver cancer mainly refers to hepatocellular carcinoma (HCC), cholangiocarcinoma, and 
hepatic angiosarcoma. HCC is considered as the third leading cause of death from cancer, primarily 
due to late symptom manifestation and unresponsiveness to treatment [162]. Hence, patients affected 
with HCC have a 5-year survival rate [163]. Persistent hepatitis B virus (HBV) infection is a leading 
cause to develop HCC. Molecular evidence suggested that viral X-gene product (HBx) has the major 
role in the etiology of HCC [164]. HBx produces a 154 amino acids protein that has been implicated as 
a cofactor or tumor promoter through its pleiotropic regulatory functions in apoptosis, DNA repair, 
chromosomic instability, proliferation, inflammation and tumorigenesis [165], through the activation 
of transcription factors such as NF-κB, c-MYC and TNF-α [166,167]. Therefore, this viral pleiotropic 
protein could have an important indirect effect on miRNA expression profile through the activation of 
key transcription factors. Int. J. Mol. Sci. 2012, 13  1366 
 
In normal liver, miR-122 corresponding to about 70% of total miRNA population is considered as a 
liver  specific  miRNA  implicated  in  systemic  metabolism.  During  HCC  carcinogenesis,  miR-122 
expression is lost; moreover restoration of miR-122 expression in cell lines can suppress malignant 
growth by directly targeting cyclin G1 expression and metastatic properties [168–170]. miR-195, one 
of  the  miR-16/15/195/424/497  family  members,  is  down-regulated  in  a  wide  variety  of  tumors 
including  colorectal  cancer;  moreover,  it  seems  to  negatively  regulate  lymph-node  metastasis  by 
targeting cyclins D1 and E1, CDK6, E2F3, suppressing tumorigenesis and blocking G1-S transition. 
miR195 down-regulation during HCC process suggested that miR-195 could have an important role in 
the control of processes that are deregulated in HCC carcinogenesis [171]. 
miR-21 contributes to HCC growth and maintenance mechanisms, probably through AKT and ERK 
pathway  activation.  It  promotes  angiogenesis  by  means  of  HIF-1a  stabilization.  miR-21  is  also 
involved in HCC metastasis and migration by directly targeting PTEN. This metastamiR can activate 
specific  matrix  metalloproteinases,  such  as  MMP2  and  MMP9,  that  are  downstream  mediators  of 
PTEN  [172].  PTEN  interacts  with  the  focal  adhesion  kinase  FAK  and  reduces  its  tyrosine 
phosphorylation.  Therefore,  PTEN  is  an  antagonist  of  metastasis  by  negatively  regulating  cell 
interactions with the extracellular matrix. Other microRNAs, such as miR-221 and miR-222, are able 
to  deregulate  PTEN.  Moreover,  these  miRNAs  also  target  the  protein  phosphatase  2A  subunit  B 
(PPP2R2A) and TIMP3, thus activating the AKT pathway and metalloproteases associated to cell 
invasion and metastasis [84,173]. 
TGF-beta is a key regulator of metastasis, which can regulate hallmarks of cancer that finally lead 
to metastasis, such as cell proliferation, differentiation, motility, adhesion and programmed cell death. 
Recently, Wang and co-workers have shown that miR-181b is transcriptionally induced by TGF-beta 
signaling  pathway  through  SMAD4.  Moreover,  miR-181  targets  TIMP3  that  is  an  inhibitor  of 
metalloprotease, inductor of apoptosis and inhibits angiogenesis, cell migration and invasion [174]. It 
is clear that the induction of metastasis through TGF-beta/SMAD4/miR-181b leads to inhibition of 
metastatic  negative  regulators  such  as  TIMP3  and  over-activation  of  metalloproteinases.  Two 
additional  microRNA  that  are  associated  to  HCC  metastasis  are  miR-143  whose  expression  is 
mediated by NF-κB [175] and miR-17-5p whose activity depends on p38 mitogen-activated protein 
kinase and increased phosphorylation of heat shock protein 27 [176]. 
6. Conclusions 
The  recent discovery  of  the  role  of  microRNAs  as  tumor-suppressor  genes  and  oncogenes  has 
added an additional level of complexity to the mechanisms leading to tumorigenesis. In particular, the 
extensive review presented here evidences that metastamiRs have emerged as new molecular players 
to regulate invasion and metastasis events in all types of cancers, including lung, prostate, colorectal, 
gastric, head and neck, cervical and hepatocellular carcinomas. Some of these miRNAs are common 
regulators  of  cell  motility  and  invasion  in  distinct  cancers  (Figure  3);  others  appear  to  be  cancer 
specific,  according  to  the  current  knowledge.  Understanding  how  metastamiRs  are  involved  in 
regulating  tumor  invasion  and  metastasis  process  will  provide  a  promising  strategy  for  the 
identification of molecular markers for progression and prognosis, for response to chemotherapy, early 
biomarkers  of  aggressive  tumors,  and  the  development  of  new  metastamiRs-based  treatments. Int. J. Mol. Sci. 2012, 13  1367 
 
However, further investigations about the role of each miRNA in each cancer are required in order to 
use them as targets for therapy, prognosis and diagnosis in the near future. 
Figure 3. MicroRNAs implicated in the regulation of metastasis. miRNAs are grouped 
according  their  roles  in  metastatic  processes:  (A)  Invasion,  motility  and  migration; 
(B) angiogenesis  and  intravasation;  and  (C)  extravasation  and  colonization  of  the 
secondary  organ.  Characterized  metastamiRs  that  conferred  (pro-metastatic)  or  repressed  
(anti-metastatic) metastatic abilities to tumoral cells are denoted in gray boxes. 
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